224 related articles for article (PubMed ID: 32619958)
1. Inhibition of phosphodiesterase IV enzyme improves locomotor and sensory complications of spinal cord injury via altering microglial activity: Introduction of Roflumilast as an alternative therapy.
Moradi K; Golbakhsh M; Haghighi F; Afshari K; Nikbakhsh R; Khavandi MM; Faghani S; Badripour A; Etemadi A; Ashraf-Ganjouei A; Bagheri S; Dehpour AR
Int Immunopharmacol; 2020 Sep; 86():106743. PubMed ID: 32619958
[TBL] [Abstract][Full Text] [Related]
2. Anti-inflammatory effects of Metformin improve the neuropathic pain and locomotor activity in spinal cord injured rats: introduction of an alternative therapy.
Afshari K; Dehdashtian A; Haddadi NS; Haj-Mirzaian A; Iranmehr A; Ebrahimi MA; Tavangar SM; Faghir-Ghanesefat H; Mohammadi F; Rahimi N; Javidan AN; Dehpour AR
Spinal Cord; 2018 Nov; 56(11):1032-1041. PubMed ID: 29959433
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiestrase-1 and 4 inhibitors ameliorate liver fibrosis in rats: Modulation of cAMP/CREB/TLR4 inflammatory and fibrogenic pathways.
Essam RM; Ahmed LA; Abdelsalam RM; El-Khatib AS
Life Sci; 2019 Apr; 222():245-254. PubMed ID: 30858122
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Effects of Azithromycin on Spinal Cord Injury in Male Wistar Rats: A Role for Inflammatory Pathways.
Rismanbaf A; Afshari K; Ghasemi M; Badripour A; Haj-Mirzaian A; Dehpour AR; Shafaroodi H
J Neurol Surg A Cent Eur Neurosurg; 2022 Sep; 83(5):411-419. PubMed ID: 34781403
[TBL] [Abstract][Full Text] [Related]
5. Roflumilast, a phosphodiesterase-4 inhibitor, improves hyperoxia-induced lung injury via anti-inflammation.
Cao HY; Yu TH; Han CH; Liu WW; Zhang PX; Tang P
Undersea Hyperb Med; 2020; 47(2):189-196. PubMed ID: 32574434
[TBL] [Abstract][Full Text] [Related]
6. Melatonin improves functional recovery in female rats after acute spinal cord injury by modulating polarization of spinal microglial/macrophages.
Zhang Y; Liu Z; Zhang W; Wu Q; Zhang Y; Liu Y; Guan Y; Chen X
J Neurosci Res; 2019 Jul; 97(7):733-743. PubMed ID: 31006904
[TBL] [Abstract][Full Text] [Related]
7. Roflumilast, type 4 phosphodiesterase inhibitor, attenuates inflammation in rats with ulcerative colitis via down-regulation of iNOS and elevation of cAMP.
El-Ashmawy NE; Khedr NF; El-Bahrawy HA; El-Adawy SA
Int Immunopharmacol; 2018 Mar; 56():36-42. PubMed ID: 29331766
[TBL] [Abstract][Full Text] [Related]
8. Current insights on clinical efficacy of roflumilast for treatment of COPD, asthma and ACOS.
Bodkhe S; Nikam M; Sherje AP; Khan T; Suvarna V; Patel K
Int Immunopharmacol; 2020 Nov; 88():106906. PubMed ID: 33182057
[TBL] [Abstract][Full Text] [Related]
9. Isorhamnetin promotes functional recovery in rats with spinal cord injury by abating oxidative stress and modulating M2 macrophages/microglia polarization.
Chen F; Hu M; Shen Y; Zhu W; Cao A; Ni B; Qian J; Yang J
Eur J Pharmacol; 2021 Mar; 895():173878. PubMed ID: 33453223
[TBL] [Abstract][Full Text] [Related]
10. Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats.
Izikki M; Raffestin B; Klar J; Hatzelmann A; Marx D; Tenor H; Zadigue P; Adnot S; Eddahibi S
J Pharmacol Exp Ther; 2009 Jul; 330(1):54-62. PubMed ID: 19386793
[TBL] [Abstract][Full Text] [Related]
11. Oral treatment with glycyrrhizin inhibits NLRP3 inflammasome activation and promotes microglial M2 polarization after traumatic spinal cord injury.
Su XQ; Wang XY; Gong FT; Feng M; Bai JJ; Zhang RR; Dang XQ
Brain Res Bull; 2020 May; 158():1-8. PubMed ID: 32092434
[TBL] [Abstract][Full Text] [Related]
12. Rolipram attenuates acute oligodendrocyte death in the adult rat ventrolateral funiculus following contusive cervical spinal cord injury.
Whitaker CM; Beaumont E; Wells MJ; Magnuson DS; Hetman M; Onifer SM
Neurosci Lett; 2008 Jun; 438(2):200-4. PubMed ID: 18455876
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma.
Al-Sajee D; Yin X; Gauvreau GM
Expert Opin Pharmacother; 2019 Apr; 20(5):609-620. PubMed ID: 30722707
[TBL] [Abstract][Full Text] [Related]
14. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.
Cazzola M; Calzetta L; Rogliani P; Matera MG
Expert Opin Drug Discov; 2016 Jul; 11(7):733-44. PubMed ID: 27169612
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice.
Suzuki O; Mizukami K; Etori M; Sogawa Y; Takagi N; Tsuchida H; Morimoto K; Goto T; Yoshino T; Mikkaichi T; Hirahara K; Nakamura S; Maeda H
J Pharmacol Sci; 2013; 123(3):219-26. PubMed ID: 24152964
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
[TBL] [Abstract][Full Text] [Related]
17. Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast.
Ding H; Li N; He X; Liu B; Dong L; Liu Y
Int Urol Nephrol; 2017 Oct; 49(10):1723-1730. PubMed ID: 28756610
[TBL] [Abstract][Full Text] [Related]
18. Roflumilast: a selective phosphodiesterase 4 inhibitor.
Christie P
Drugs Today (Barc); 2005 Oct; 41(10):667-75. PubMed ID: 16389409
[TBL] [Abstract][Full Text] [Related]
19. Influence of roflumilast on sepsis mice through the JAK/STAT signaling pathway.
Chang X; Hu LF; Ma XJ; Yin J; Liu XY; Li JB
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1335-1341. PubMed ID: 30779101
[TBL] [Abstract][Full Text] [Related]
20. Roflumilast: Modulating neuroinflammation and improving motor function and depressive symptoms in multiple sclerosis.
Wang Z; Zhang Y; Chai J; Wu Y; Zhang W; Zhang Z
J Affect Disord; 2024 Apr; 350():761-773. PubMed ID: 38220100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
